Slide 1: Q1 CellaVision Interim Report January-March 2024
Q1 CellaVision Interim Report January-March 2024 A Solid Start to the Year Organic sales growth: Q1, 2024: 22% (-21) EBITDA margin: Q1, 2024: 29% (25) January 1 – March 31, 2024 Net sales increased by 22% (-14) to SEK 170 m (139). Sales increased organically by 22% (-21), currency effect 0% (7). EBI
Slide 2: CEO's Comment
CEO’s Comment CellaVision had a solid start to the year, with all Sales in the EMEA region increased by 21 The Strategic Alliance Agreement with Sysmex regions contributing to growth. There is strong percent, reaching SEK 79 m (65). Our ecosystem Corporation entered in the quarter, has traction for
Slide 3: Sales, Earning and Investments
Sales, Earning and Investments Net Sales and Currency Effects The lower gross margin during the quarter compared to the Net Financial Items Net sales for the Group’s first quarter increased by 22 percent corresponding quarter of the previous year can be explained The interest-bearing liabilities in
Slide 4: Cash Flow
Cash Flow The cash and cash equivalents at the end of the quarter amounted to SEK 167 m (93). In addition, CellaVision has an unutilized overdraft facility of SEK 30 m (30). The cash flow from operating activities increased to SEK 71 m (19) for the quarter. The increase is attributed to an improved
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 72 m (59) EMEA: SEK 79 m (65) APAC: SEK 19 m (16) In the Americas, sales increased by 23 percent to SEK 72 m (59) In EMEA, sales increased by 21 percent to SEK 79 m (65) when In APAC, the momentum observed in the latter half of 2023 compared to t
Slide 6: Research and Development
Research and Development Improving healthcare through continuous Progress on advancing the Fourier innovation is a fundamental ambition Ptychographic Microscopy (FPM) technology of CellaVision. The company devotes continues, with ongoing patent filings considerable resources to research for new inno
Slide 7: The Nomination Committee and the Annual General Meeting in 2024
The Nomination Committee and the Annual General Meeting in 2024 The Nomination Committee’s summarized proposal regarding Board before the Annual General . Meeting 2024 The Nomination Committee proposes the current Chairman Mikael Worning to be re-elected as Chairman of the Board and proposes re-elec
Slide 8: Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ' 000 SEK Note Jan-Mar 2024 Jan-Mar 2023 Jan-Dec 2023 Net sales 4 170,080 139,096 677,292 Cost of goods sold -58,014 -42,236 -214,251 Gross profit 112,065 96,860 463,040 Sales and marketing expenses -32,
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Jan-Mar 2024 Jan-Mar 2023 Jan-Dec 2023 Earnings per share, before and after dilution, SEK */ 1.26 0.81 5.46 Equity per share, SEK 31.81 27.85 30.04 Number of shares outstanding 23,851,547 23,851,547 23,851,547 Average number of shares outstanding 23,851,547 23,851,547 2
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 03/31/2024 03/31/2023 12/31/2023 Assets Intangible assets 5 451 295 410 342 433 223 Tangible assets 6 126 420 119 088 125 502 Financial assets 7 3 942 4 965 4 396 Inventory 122 251 152 031 126 038 Trade receivables 7 81 114 86 504 97 797 Othe
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ' 000 SEK Jan-Mar 2024 Jan-Mar 2023 Jan-Dec 2023 Result before taxes 38,243 24,359 164,222 Adjustment for items not included in cash flow 16,761 10,100 49,382 Income tax paid -5,244 -3,289 -27,561 Cash flow from operating activities before changes in
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ' 000 SEK Jan-Mar 2024 Jan-Mar 2023 Jan-Dec 2023 Net sales 127,620 103,054 523,473 Cost of goods sold -33,447 -19,995 -118,814 Gross profit 94,173 83,059 404,659 Sales and marketing expenses -21
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 03/31/2024 03/31/2023 12/31/2023 Assets Intangible assets 29,187 32,178 29,935 Tangible assets 5,385 5,882 5,770 Deferred tax assets 496 733 496 Long term receivables from group companies 35,728 32,137 35,507 Financial assets 262,658 263,
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has CellaVision is exposed to several risks, which may impact the Group’s development to a greater been prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES Amounts in ' 000 SEK 03/31/2024 03/31/2023 The disclosed value of financial assets, trade receivables, other receivables, cash and bank, Capitalised expenditure for development 223,660 174,608 trade payables, and other
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures The company presents certain financial measures in the interim report which are not defined according to IFRS. The to IFRS. Definitions of measures which are not defined noncontrolling interests as a percentage of total assets. financial metrics are used
Slide 17: Questions Concerning the Report
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 7:20 a.m. CEST on April 25, 2024. CellaVision is listed on the Nasdaq
Slide 18: This is CellaVision
This is CellaVision About Us Our Strategic Ambition: The power of focus Mission CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy Our mission is to advance laboratory workflow and that develops and sells its own leading sol